GSK NiQuitin ads
This article was originally published in The Tan Sheet
Executive Summary
National press ad, London Underground poster for GSK's NiQuitin CQ smoking cessation lozenge deemed "misleading" by Britain's Advertising Standards Authority in Sept. 11 ruling. Ad watchdog upheld a complaint brought by rival Pharmacia Consumer Healthcare challenging claim NiQuitin CQ can "triple your chances of success." In its defense, GSK maintains claim was based on a study of over 1,800 UK and U.S. smokers, which found 23.6% of participants in active arm achieved cessation, compared with 10.2% of those in control arm. GSK rounded up the odds ratio of 2.76 to give the "triple" claim. However, ASA concludes the inflated ratio "did not justify the claim" and recommends GSK amend the ads with help from the Committee of Advertising Practice Copy Advice...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.